ストックスクリーナーアプリを入手
0.58
7.30%
-0.0457
アフターアワーズ：
.61
0.03
+5.17%
前日終値:
$0.6257
開ける：
$0.62
24時間の取引高:
2.37M
Relative Volume:
3.07
時価総額：
$34.29M
収益：
-
当期純損益:
$-41.95M
株価収益率:
-0.162
EPS:
-3.58
ネットキャッシュフロー:
$-38.34M
1週間 パフォーマンス:
-8.82%
1か月 パフォーマンス:
-0.19%
6か月 パフォーマンス:
-79.02%
1年 パフォーマンス:
+26.03%
1日の値動き範囲:
$0.55
$0.66
1週間の範囲:
$0.55
$0.70
52週間の値動き範囲:
$0.4401
$5.8299
Elevation Oncology Inc Stock (ELEV) Company Profile
ELEV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.58 | 34.29M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2024-03-01 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-05-30 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2021-12-23 | 開始されました | H.C. Wainwright | Buy |
Elevation Oncology Inc (ELEV) 最新ニュース
Items Tagged with 'ESMO IO 2024' - BioWorld Online
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - The Eastern Progress Online
Elevation Oncology nominates HER3 ADC as development candidate - BioWorld Online
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion - ShareCast
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
Elevation Oncology Inc licences Synaffix BV’s ADC platform - European Biotechnology News
Synaffix out-licenses ADC technology to Elevation Oncology - The Pharma Letter
Elevation Oncology selects EO-1022 as HER3 ADC candidate - Investing.com
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors - PR Newswire
Elevation Oncology Unveils Promising HER3 ADC Candidate for Multiple Cancer Types - StockTitan
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 - PR Newswire
Elevation Oncology Shares Tumble 39% On $50 Mln Stock-And-Warran… - Marketscreener.com
ELEVElevation Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Five things for pharma marketers to know for Friday morning - MM+M Online
Logos Global Management LP Adjusts Stake in Elevation Oncology I - GuruFocus.com
OrbiMed Advisors LLC Increases Stake in Elevation Oncology Inc - GuruFocus.com
Biotechnology Value Fund L P's Strategic Acquisition in Elevatio - GuruFocus.com
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readout - Investing.com
Goldman Sachs Group Inc's Strategic Acquisition in Elevation Onc - GuruFocus.com
Elevation Oncology’s Q3 2024 Highlights and Financial Report - TipRanks
Elevation Oncology's Cancer Drug Shows 43% Response Rate, Secures FDA Fast Track | ELEV Stock News - StockTitan
Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Zacks Investment Research
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View - Yahoo Finance
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - MSN
Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News
Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex
It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News
Elevation Oncology Inc (ELEV)’s stock price range in the last year - US Post News
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock - MSN
Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance
In the Green: Elevation Oncology Inc (ELEV) Closes at 0.52, Up/Down -3.69 from Previous Day - The Dwinnex
Taking on analysts’ expectations and winning: Elevation Oncology Inc (ELEV) - SETE News
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Market Momentum Report: Elevation Oncology Inc (ELEV)’s Positive Close at 0.59 - The Dwinnex
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readouts - Investing.com
Should investors be concerned about Elevation Oncology Inc (ELEV)? - US Post News
Elevation Oncology Inc (ELEV) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Elevance Health Inc [ELV] PERU RAMIRO G sells 753 Shares for $0.4 million - Knox Daily
Check out these key findings about Elevation Oncology Inc (ELEV) - SETE News
Elevation Oncology Inc (ELEV) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):